TrialFrontiers in immunology2022

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial.

Zhi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.